bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Information from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
Authors: Ibrahim Ahmed Atef , Schmithals Christian , Kowarz Erik , Köberle Verena , Kakoschky Bianca , Pleli Thomas , Kollmar Otto , Nitsch Scarlett , Waidmann Oliver , Finkelmeier Fabian , Zeuzem Stefan , Korf Horst-Werner , Schmid Tobias , Weigert Andreas , Kronenberger Bernd , Marschalek Rolf , Piiper Albrecht
Published: April 2023

Supplementary Information
Supplementary Fig. S1 from Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition
Authors: Ibrahim Ahmed Atef , Schmithals Christian , Kowarz Erik , Köberle Verena , Kakoschky Bianca , Pleli Thomas , Kollmar Otto , Nitsch Scarlett , Waidmann Oliver , Finkelmeier Fabian , Zeuzem Stefan , Korf Horst-Werner , Schmid Tobias , Weigert Andreas , Kronenberger Bernd , Marschalek Rolf , Piiper Albrecht
Published: April 2023

Supplementary Fig. S1. Apoptosis is not responsible for down-regulation of Dicer in HepG2 under hypoxic conditions. Western blot analysis of protein extracts from HepG2 cells cultured for 24 h under hypoxia (1% O2) (H) or normoxia (N) using anti-cleaved caspase-3 antibody. For positive control, HepG2 cells were treated with BI 2536 for 48 h with the indicated concentrations.
Figure S3 from Downregulation of MicroRNA-644a Promotes Esophageal Squamous Cell Carcinoma Aggressiveness and Stem Cell–like Phenotype via Dysregulation of PITX2
Authors: Zhang Jia-Xing , Chen Zhen-Hua , Xu Yi , Chen Jie-Wei , Weng Hui-Wen , Yun Miao , Zheng Zou-San , Chen Cui , Wu Bing-Li , Li En-Min , Fu Jian-Hua , Ye Sheng , Xie Dan
Published: April 2023

Down-regulation of miR-644a restores PITX2 expression in KYSE-410 cells. A, down-regulation of miR-644a significantly increased the luciferase activity that carried wt but not mt 3'-UTR of PITX2. B and C, down-regulation of miR-644a significantly increased PITX2 mRNA (B) and protein (C) levels of KYSE-410 cells. **P<0.01. *P<0.05.
Supplementary Tables from TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding
Authors: Petrova Penka S. , Viller Natasja Nielsen , Wong Mark , Pang Xinli , Lin Gloria H.Y. , Dodge Karen , Chai Vien , Chen Hui , Lee Vivian , House Violetta , Vigo Noel T. , Jin Debbie , Mutukura Tapfuma , Charbonneau Marilyse , Truong Tran , Viau Stephane , Johnson Lisa D. , Linderoth Emma , Sievers Eric L. , Maleki Vareki Saman , Figueredo Rene , Pampillo Macarena , Koropatnick James , Trudel Suzanne , Mbong Nathan , Jin Liqing , Wang Jean C.Y. , Uger Robert A.
Published: April 2023

These four supplementary tables summarize the following: Supplementary Table 1. TTI-621 binding to human tumor cell lines Supplementary Table 2. TTI-621 binding to human primary tumor samples Supplementary Table 3. TTI-621 binding to peripheral blood cells of healthy donors Supplementary Table 4: TTI-621 Potency In Vitro
Supplementary Methods from Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer
Authors: Pietrantonio Filippo , Vernieri Claudio , Siravegna Giulia , Mennitto Alessia , Berenato Rosa , Perrone Federica , Gloghini Annunziata , Tamborini Elena , Lonardi Sara , Morano Federica , Picciani Benedetta , Busico Adele , Volpi Chiara Costanza , Martinetti Antonia , Battaglin Francesca , Bossi Ilaria , Pellegrinelli Alessio , Milione Massimo , Cremolini Chiara , Di Bartolomeo Maria , Bardelli Alberto , de Braud Filippo
Published: April 2023

Next generation sequencing Immunohistochemistry for HER-2 and MET Dual color silver in situ hybridization (SISH) for HER-2 and MET
Supplementary Figure 1 from Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer
Authors: Pietrantonio Filippo , Vernieri Claudio , Siravegna Giulia , Mennitto Alessia , Berenato Rosa , Perrone Federica , Gloghini Annunziata , Tamborini Elena , Lonardi Sara , Morano Federica , Picciani Benedetta , Busico Adele , Volpi Chiara Costanza , Martinetti Antonia , Battaglin Francesca , Bossi Ilaria , Pellegrinelli Alessio , Milione Massimo , Cremolini Chiara , Di Bartolomeo Maria , Bardelli Alberto , de Braud Filippo
Published: April 2023

Supplementary Figure 1: Patients with acquired MET amplification have shorter PFS as compared to those with MET-negative tumors. PFS duration expressed as month time units is shown for individual patients with acquired MET amplification (blue histograms) and MET-negative (red histograms) tumors (panel A). Kaplan Meier curves show shorter median PFS of MET-amplified (blue) as compared with MET-negative (red) patients; moreover, around 40% and 15% patients MET-negative (but none of MET-amplified subjects) were still progression-free at 10 and even 20 months, respectively (panel B).
Supplementary Figure 2 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
Authors: Vigneri Paolo , Stagno Fabio , Stella Stefania , Cupri Alessandra , Forte Stefano , Massimino Michele , Antolino Agostino , Siragusa Sergio , Mannina Donato , Impera Stefana Stella , Musolino Caterina , Malato Alessandra , Mineo Giuseppe , Tomaselli Carmela , Murgano Pamela , Musso Maurizio , Morabito Fortunato , Molica Stefano , Martino Bruno , Manzella Livia , Müller Martin C. , Hochhaus Andreas , Raimondo Francesco Di
Published: April 2023

Figure 2. Comparison of BCR-ABL/ABL levels at diagnosis in patients achieving an OR or failing IM. Patients were stratified according to their IM response scored following the 2013 ELN criteria (optimal vs failure). BCR-ABL transcripts - using ABL as a reference gene - were determined for each group and depicted as boxplots delimited by the 25th (lower) and 75th (upper) percentile. Horizontal lines above and below each boxplot indicate the 5th and 95th percentile, respectively. Thick lines in each boxplot represent median BCR-ABL/ABL in each patient group. Patients failing IM displayed significantly higher BCR-ABL transcripts at diagnosis (p<0.005).
Supplementary methods, results, suppl figure legends from Cyst Fluid Telomerase Activity Predicts the Histologic Grade of Cystic Neoplasms of the Pancreas
Authors: Hata Tatsuo , Dal Molin Marco , Suenaga Masaya , Yu Jun , Pittman Meredith , Weiss Matthew , Canto Marcia I. , Wolfgang Christopher , Lennon Anne Marie , Hruban Ralph H. , Goggins Michael
Published: April 2023

Further description of telomerase assay, information about cyst fluid storage, supplementary figure legends
Supplementary Table S5 from Cyst Fluid Telomerase Activity Predicts the Histologic Grade of Cystic Neoplasms of the Pancreas
Authors: Hata Tatsuo , Dal Molin Marco , Suenaga Masaya , Yu Jun , Pittman Meredith , Weiss Matthew , Canto Marcia I. , Wolfgang Christopher , Lennon Anne Marie , Hruban Ralph H. , Goggins Michael
Published: April 2023

Supplementary Table S5;Diagnostic performance of telomerase activity in cases stratified by imaging features among discovery set cases
Supplementary Table S4 from Cyst Fluid Telomerase Activity Predicts the Histologic Grade of Cystic Neoplasms of the Pancreas
Authors: Hata Tatsuo , Dal Molin Marco , Suenaga Masaya , Yu Jun , Pittman Meredith , Weiss Matthew , Canto Marcia I. , Wolfgang Christopher , Lennon Anne Marie , Hruban Ralph H. , Goggins Michael
Published: April 2023

Supplementary Table S4; Diagnostic performance of using telomerase activity in combination with clinical predictors of invasive cancer or high-grade dysplasia among discovery set cases
Figure S1 from Tumor Heterogeneity Predicts Metastatic Potential in Colorectal Cancer
Authors: Joung Je-Gun , Oh Bo Young , Hong Hye Kyung , Al-Khalidi Hisham , Al-Alem Faisal , Lee Hae-Ock , Bae Joon Seol , Kim Jinho , Cha Hong-Ui , Alotaibi Maram , Cho Yong Beom , Hassanain Mazen , Park Woong-Yang , Lee Woo Yong
Published: April 2023

Supplementary Figure 1. Survival plot using Kaplan-Meier survival analysis between two patient groups with high- and low-heterogeneity.
SUPPLEMENTARY FIGURES: Antihypoxic Effects of Myo-Inositol Trispyrophosphate on Vasculature and Therapy of Colorectal Liver Metastasis from Antihypoxic Potentiation of Standard Therapy for Experimental Colorectal Liver Metastasis through Myo-Inositol Trispyrophosphate
Authors: Limani Perparim , Linecker Michael , Kachaylo Ekaterina , Tschuor Christoph , Kron Philipp , Schlegel Andrea , Ungethuem Udo , Jang Jae Hwi , Georgiopoulou Stavroula , Nicolau Claude , Lehn Jean-Marie , Graf Rolf , Humar Bostjan , Clavien Pierre-Alain
Published: April 2023

Supplementary Figure 1. ITPP increases O2 dissociation from hemoglobin. Supplementary Figure 2. Impact of ITPP on tumor burden, hypoxia and survival in the CT- 26/BALB model. Supplementary Figure 3. Impact of ITPP on metabolic and immune parameters in the CT- 26/BALB model at day 17. Supplementary Figure 4. Impact of ITPP on malignant tumor phenotype in the CT-26/BALB model at day 17. Supplementary Figure 5. Impact of oxygen levels and ITPP on cancer cells in vitro. One day after seeding MC-38 and CT-26 cells at hypoxia, cells were exposed or not to normoxia (A-C), or exposed to ITPP or saline (D-F) for 24h. Supplementary Figure 6. Impact of ITPP on tumor vasculature in the MC-38/B6 model at day 17. Supplementary Figure 7. Impact of ITPP on tumor vasculature in the CT-26/BALB model at day 17. Supplementary Figure 8. Long-term impact of ITPP on hypoxic response and tumor vasculature in the CT-26/BALB model.
Supplementary Figure S4 from Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in RETM918T Tumors
Authors: Mancikova Veronika , Montero-Conde Cristina , Perales-Paton Javier , Fernandez Agustin , Santacana María , Jodkowska Karolina , Inglada-Pérez Lucia , Castelblanco Esmeralda , Borrego Salud , Encinas Mario , Matias-Guiu Xavier , Fraga Mario , Robledo Mercedes
Published: April 2023

Functional annotation clustering by DAVID (http://david.abcc.ncifcrf.gov/home.jsp) of the genes with aberrant methylation and expression among RETM918T-positive carcinomas. Cytokine-cytokine interaction and Jak/STAT pathway are highlighted in dark grey.
Appendix from The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population
Authors: Heller Glenn , Fizazi Karim , McCormack Robert , Molina Arturo , MacLean David , Webb Iain J. , Saad Fred , de Bono Johann S. , Scher Howard I.
Published: April 2023

Methodology Details
Supplementary Figure S4 from Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia
Authors: Amin Nisar A. , Balasubramanian Sriram , Saiya-Cork Kamlai , Shedden Kerby , Hu Nan , Malek Sami N.
Published: April 2023

Genomic complexity as measured through SNP 6.0 profiling does not associate with ibrutinib-induced cell death in CLL:
Supplemental Figure 7 from CTLA-4 Limits Anti-CD20–Mediated Tumor Regression
Authors: Ren Zhenhua , Guo Jingya , Liao Jing , Luan Yan , Liu Zhida , Sun Zhichen , Liu Xiaojuan , Liang Yong , Peng Hua , Fu Yang-Xin
Published: April 2023

Supplementary Figure 7. Model for generation of anti-tumor T-cell response induced by anti-CD20 treatment.
Supplemental Table 1 from Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility
Authors: Künkele Annette , Taraseviciute Agne , Finn Laura S. , Johnson Adam J. , Berger Carolina , Finney Olivia , Chang Cindy A. , Rolczynski Lisa S. , Brown Christopher , Mgebroff Stephanie , Berger Michael , Park Julie R. , Jensen Michael C.
Published: April 2023

Supplemental Table 1. Release criteria.
Supplemental Figure 2 from Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility
Authors: Künkele Annette , Taraseviciute Agne , Finn Laura S. , Johnson Adam J. , Berger Carolina , Finney Olivia , Chang Cindy A. , Rolczynski Lisa S. , Brown Christopher , Mgebroff Stephanie , Berger Michael , Park Julie R. , Jensen Michael C.
Published: April 2023

Supplemental Figure 2 CD171 tissue expression in rhesus shown by TMA.
Supplementary Table 2 from A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Authors: Czuczman Myron S. , Trněný Marek , Davies Andrew , Rule Simon , Linton Kim M. , Wagner-Johnston Nina , Gascoyne Randy D. , Slack Graham W. , Brousset Pierre , Eberhard David A. , Hernandez-Ilizaliturri Francisco J. , Salles Gilles , Witzig Thomas E. , Zinzani Pier Luigi , Wright George W. , Staudt Louis M. , Yang Yandan , Williams P. Mickey , Lih Chih-Jian , Russo Jacqueline , Thakurta Anjan , Hagner Patrick , Fustier Pierre , Song Dale , Lewis Ian D.
Published: April 2023

List of Primer Sequences
Supplementary Table 1 from A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Authors: Czuczman Myron S. , Trněný Marek , Davies Andrew , Rule Simon , Linton Kim M. , Wagner-Johnston Nina , Gascoyne Randy D. , Slack Graham W. , Brousset Pierre , Eberhard David A. , Hernandez-Ilizaliturri Francisco J. , Salles Gilles , Witzig Thomas E. , Zinzani Pier Luigi , Wright George W. , Staudt Louis M. , Yang Yandan , Williams P. Mickey , Lih Chih-Jian , Russo Jacqueline , Thakurta Anjan , Hagner Patrick , Fustier Pierre , Song Dale , Lewis Ian D.
Published: April 2023

Investigator's Choice (IC) Dosing Regimens
Supplementary Data from Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer
Authors: Siravegna Giulia , Sartore-Bianchi Andrea , Nagy Rebecca J. , Raghav Kanwal , Odegaard Justin I. , Lanman Richard B. , Trusolino Livio , Marsoni Silvia , Siena Salvatore , Bardelli Alberto
Published: April 2023

Supp. Table 1 Summary of tissue and ctDNA results and response data
Supplemental Figure 5 from Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade
Authors: Dovedi Simon J. , Cheadle Eleanor J. , Popple Amy L. , Poon Edmund , Morrow Michelle , Stewart Ross , Yusko Erik C. , Sanders Catherine M. , Vignali Marissa , Emerson Ryan O. , Robins Harlan S. , Wilkinson Robert W. , Honeychurch Jamie , Illidge Timothy M.
Published: April 2023

Representative staining for PD-L1 on tumor cells (CD45-) and CD11b+Gr1+ cells
Supplemental Patients, Methods, and Tables from Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis
Authors: Marachelian Araz , Villablanca Judith G. , Liu Cathy W. , Liu Betty , Goodarzian Fariba , Lai Hollie A. , Shimada Hiroyuki , Tran Hung C. , Parra Jaime A. , Gallego Richard , Bedrossian Nora , Young Sabrina , Czarnecki Scarlett , Kennedy Rebekah , Weiss Brian D. , Goldsmith Kelly , Granger Meaghan , Matthay Katherine K. , Groshen Susan , Asgharzadeh Shahab , Sposto Richard , Seeger Robert C.
Published: April 2023

Table A1. Therapies received for samples submitted on this study; Table A2. Genes and Primer and Probe Sets for NB5 assay; Table A3. Clinical Evaluations and NB5 TLDA Assays Performed; Table A4. Contribution of Individual Gene to NB5 Signature and AUC.
Supplementary Figure 1 from Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI
Authors: Panek Rafal , Welsh Liam , Baker Lauren C.J. , Schmidt Maria A. , Wong Kee H. , Riddell Angela M. , Koh Dow-Mu , Dunlop Alex , Mcquaid Dualta , d'Arcy James A. , Bhide Shreerang A. , Harrington Kevin J. , Nutting Christopher M. , Hopkinson Georgina , Richardson Cheryl , Box Carol , Eccles Suzanne A. , Leach Martin O. , Robinson Simon P. , Newbold Kate L.
Published: April 2023

Example of coronal T2-weighted image of two simultaneously scanned mice bearing CALR HNSCC xenografts (mice IV and V, tumors are marked with arrows) and a phantom containing 1.5 mM gadoterate meglumine (Dotarem, Guerbet, Villepinte, France) in saline, acquired using the asymmetric high-resolution three element receive coil.
Supplementary Data from MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer
Authors: Parikh Aparna R. , Lee Fa-Chyi , Yau Linda , Koh Han , Knost James , Mitchell Edith P. , Bosanac Ivan , Choong Nicholas , Scappaticci Frank , Mancao Christoph , Lenz Heinz-Josef
Published: April 2023

Supplementary Data from MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer
Figure S5_2 from Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma
Authors: Caumanns Joseph J. , Berns Katrien , Wisman G. Bea A. , Fehrmann Rudolf S.N. , Tomar Tushar , Klip Harry , Meersma Gert J. , Hijmans E. Marielle , Gennissen Annemiek M.C. , Duiker Evelien W. , Weening Desiree , Itamochi Hiroaki , Kluin Roelof J.C. , Reyners Anna K.L. , Birrer Michael J. , Salvesen Helga B. , Vergote Ignace , van Nieuwenhuysen Els , Brenton James , Braicu E. Ioana , Kupryjanczyk Jolanta , Spiewankiewicz Beata , Mittempergher Lorenza , Bernards René , van der Zee Ate G.J. , de Jong Steven
Published: April 2023

Supplementary Figure 5 | Clustering (n=106) and survival analysis (n=70) on kinome mutations and CNA. (A) Disease-specific survival of patients (n=70) grouped on ARID1A status, (B) PIK3CA status and (C) ARID1A + PIK3CA status. (D) Consensus clustering, with maximum group count set to 10 and clustering optimization with 1000 repetitions maximum, shows adding of tumors (n=106) as consensus index (horizontally) and empirical cumulative distribution (vertically) for 1-10 clusters. (E) Area under the curve plot of decrease in friction from 1-10 clusters. (F) Heatmap distribution of tumors in 8 clusters. (G) Disease-specific survival of patients (n=70) in 8 clusters, (H) cluster 3 vs. other clusters. (I) Disease-specific survival in advanced stage OCCC patients (FIGO 2C-4), Log rank (Mantel-Cox) was used for statistical analysis. (J) Nonsynonymous mutation distribution in genes involved in the frequently mutated PI3K/AKT/mTOR (blue) and MAPK pathway (yellow), ERBB family of receptor tyrosine kinases (green) and DNA repair pathway (red) as well as ARID1A and PALB2 are shown with OncoPrint. CNA in each mutated gene are added. The 106 OCCC tumors that were both kinome sequenced and SNP arrayed are shown on the horizontal axis grouped on tumor clusters and ordered on total event frequency in the subsequently altered pathways. (K) Oncoprint from advanced stage patients in cluster 3 vs. other clusters, shown on the horizontal axis grouped on tumor clusters and ordered on total event frequency in the subsequent altered pathways, ordered as aforementioned.
Supplementary Figure S2 from Targeted Proteomics Identifies Proteomic Signatures in Liquid Biopsies of the Endometrium to Diagnose Endometrial Cancer and Assist in the Prediction of the Optimal Surgical Treatment
Authors: Martinez-Garcia Elena , Lesur Antoine , Devis Laura , Cabrera Silvia , Matias-Guiu Xavier , Hirschfeld Marc , Asberger Jasmin , van Oostrum Jan , Casares de Cal María de los Ángeles , Gómez-Tato Antonio , Reventos Jaume , Domon Bruno , Colas Eva , Gil-Moreno Antonio
Published: April 2023

Supplementary Figure 2. CTNB1, XPO2 and CAPG study according to the TCGA classification.
Supplementary Table S2 from Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo
Authors: Siemeister Gerhard , Mengel Anne , Fernández-Montalván Amaury E. , Bone Wilhelm , Schröder Jens , Zitzmann-Kolbe Sabine , Briem Hans , Prechtl Stefan , Holton Simon J. , Mönning Ursula , von Ahsen Oliver , Johanssen Sandra , Cleve Arwed , Pütter Vera , Hitchcock Marion , von Nussbaum Franz , Brands Michael , Ziegelbauer Karl , Mumberg Dominik
Published: April 2023

Anti-proliferative cell line profile of BAY 1816032
Supplementary Figure 1 from Radiotherapy for Non–Small Cell Lung Cancer Induces DNA Damage Response in Both Irradiated and Out-of-field Normal Tissues
Authors: Siva Shankar , Lobachevsky Pavel , MacManus Michael P. , Kron Tomas , Möller Andreas , Lobb Richard J. , Ventura Jessica , Best Nickala , Smith Jai , Ball David , Martin Olga A.
Published: April 2023

Association between PTV volume and excess (above the baseline) average number of foci per cell (a) and excess proportion of cells with {greater than or equal to} 6 γ-H2AX foci (b) at 1-hour and 24-hours.
figure S2 from BMI1 Drives Metastasis of Prostate Cancer in Caucasian and African-American Men and Is A Potential Therapeutic Target: Hypothesis Tested in Race-specific Models
Authors: Ganaie Arsheed A. , Beigh Firdous H. , Astone Matteo , Ferrari Marina G. , Maqbool Raihana , Umbreen Syed , Parray Aijaz S. , Siddique Hifzur R. , Hussain Tabish , Murugan Paari , Morrissey Colm , Koochekpour Shahriar , Deng Yibin , Konety Badrinath R. , Hoeppner Luke H. , Saleem Mohammad
Published: April 2023

Supplementary Figure 2. Inhibition of colony formation by BMI1 inhibitor and Docetaxel combination in African American and Caucasian CaP models on Colony-formation assay as described in material and methods.
Supplementary Dataset 3 from Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma
Authors: Heske Christine M. , Davis Mindy I. , Baumgart Joshua T. , Wilson Kelli , Gormally Michael V. , Chen Lu , Zhang Xiaohu , Ceribelli Michele , Duveau Damien Y. , Guha Rajarshi , Ferrer Marc , Arnaldez Fernanda I. , Ji Jiuping , Tran Huong-Lan , Zhang Yiping , Mendoza Arnulfo , Helman Lee J. , Thomas Craig J.
Published: April 2023

Proteomic outcomes
Supplementary from Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance
Authors: Turner David C. , Kondic Anna G. , Anderson Keaven M. , Robinson Andrew G. , Garon Edward B. , Riess Jonathan Wesley , Jain Lokesh , Mayawala Kapil , Kang Jiannan , Ebbinghaus Scot W. , Sinha Vikram , de Alwis Dinesh P. , Stone Julie A.
Published: April 2023

Fig S1. Kaplan-Meier plots of overall survival, stratified by pembrolizumab dose, demonstrate similarity of efficacy across a 5-fold dose range (2 to 10 mg/kg Q3W) in A) advanced ipilimumab-refractory melanoma, KEYNOTE-002 (Cox HR 0.98; 95% CI 0.94-1.02) and B) advanced, previously-treated PD-L1 positive NSCLC, KEYNOTE-010 (Cox HR 0.98; 95%CI 0.95-1.01). Subjects with at least one available PK measurement were included. Fig S2. Overall pooled exposure-response patterns demonstrate trends incongruent with similarity in dose-response patterns across 2 to 10 mg/kg in A) advanced ipilimumab-refractory melanoma, KEYNOTE-002 and B) advanced, previously-treated PD-L1 positive NSCLC, KEYNOTE-010. Fig S3. Similarity in OS between respective within-dose exposure quartiles at 2 and 10 mg/kg shows E-R patterns from pooled data (Fig S2 above) to be misleading in A-B) advanced ipilimumab-refractory melanoma, KEYNOTE-002 and C-D) advanced, previously-treated PD-L1 positive NSCLC, KEYNOTE-010. Fig S4. Kaplan-Meier plots of OS by all CL0 quartiles in KEYNOTE-002 (melanoma; left) and KEYNOTE-010 (previously-treated NSCLC; right) using the complete case datasets. Fig S5. Kaplan-Meier plots of OS by baseline clearance (CL0) quartiles in advanced, previously-untreated NSCLC with PD-L1 expression at least 50 percent. Pembrolizumab administered at 200 mg Q3W (KEYNOTE-024; n=152). Subjects with at least one available PK measurement were included. Fig S6. Forest plot of Docetaxel-treated NSCLC Cox proportional hazards model-estimated overall survival hazard ratios (n=249). Complete case dataset was used. Supplementary Table S1. Source Profile of PK - Overall Survival Analysis Datasets (KEYNOTE-002 and -010) Used in Multivariate Cox Models. Supplementary Table S2. Demographics and Baseline Characteristics for Subjects with {greater than or equal to} 1 Pembrolizumab PK Measurement (KEYNOTE-010/-024 and -002). Supplementary Table S3. Comparison of Univariate HR Results using Baseline Clearance from Time-dependent PK Model Versus a Steady-state Clearance from a Static PK Model Shows the Choice of Exposure Interval is Not Expected to Impact Rank Order of Exposure Estimates and that a Modest, Time-dependent Change in Pembrolizumab Clearance Does Not Meaningfully Alter Interpretations Described in this Study. Supplementary Table S4. Protocol-specified Pharmacokinetic Sampling Strategy.
Supplementary Figure 1 from Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors
Authors: Von Hoff Daniel D. , Rasco Drew W. , Heath Elisabeth I. , Munster Pamela N. , Schellens Jan H.M. , Isambert Nicolas , Tourneau Christophe Le , O'Neil Bert , Mathijssen Ron H.J. , Lopez-Martin Jose A. , Edenfield W. Jeff , Martin Miguel , LoRusso Patricia M. , Bray Gordon L. , DiMartino Jorge , Nguyen Aaron , Liu Kejian , Laille Eric , Bendell Johanna C.
Published: April 2023

Mean total carboplatin plasma concentration following carboplatin administration alone or with CC-486 in part 1 arm A
Table S2 from MELK Inhibition in Diffuse Intrinsic Pontine Glioma
Authors: Meel Michaël H. , de Gooijer Mark C. , Guillén Navarro Miriam , Waranecki Piotr , Breur Marjolein , Buil Levi C.M. , Wedekind Laurine E. , Twisk Jos W.R. , Koster Jan , Hashizume Rintaro , Raabe Eric H. , Montero Carcaboso Angel , Bugiani Marianna , van Tellingen Olaf , van Vuurden Dannis G. , Kaspers Gertjan J.L. , Hulleman Esther
Published: April 2023

List of off-target effects of OTSSP167 occurring at concentrations lower than 50nM, derived from the publicly available phosphoproteomics database at http://proteomicsdb.org.
Supplement from Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma
Authors: Przybyl Joanna , Chabon Jacob J. , Spans Lien , Ganjoo Kristen N. , Vennam Sujay , Newman Aaron M. , Forgó Erna , Varma Sushama , Zhu Shirley , Debiec-Rychter Maria , Alizadeh Ash A. , Diehn Maximilian , van de Rijn Matt
Published: April 2023

Figure S1 Summary of CAPP-Seq and GRP findings in plasma specimens of 7 LMS patients. Figure S2 Specificity and sensitivity of ctDNA detection by CAPP-Seq in LMS patients. Figure S3 Individual DNA copy number alteration profiles of 22 tumor specimens from 7 LMS patients. CN - copy number Figure S4 UCSC Genome Browser view of genomic region 11q24.3-q25 that was consistently lost across all tumor specimens in patients LMS2, LMS3, LMS4, LMS5 and LMS7. Figure S5 Correlation between ctDNA levels detected by CAPP-Seq (represented as VAF) and GRP (represented as percent of genome altered by copy number alterations). Table S1 Summary of clinical features of 9 LMS patients Table S2 LMS-specific CAPP-Seq selector. Table S3 Tumor specimens used for CAPP-Seq and SNP array analysis. Table S4 Depth of sequencing and % of on-target reads by CAPP-Seq. Table S5 Summary statistics for GRP. Table S6 Input of cfDNA used for CAPP-Seq and GRP. Table S7 Summary of quality control metrics from OncoScan FFPE Assay and the extent of CNAs in 22 LMS tumor specimens.
Supplementary Data from PRMT5 Circular RNA Promotes Metastasis of Urothelial Carcinoma of the Bladder through Sponging miR-30c to Induce Epithelial–Mesenchymal Transition
Authors: Chen Xin , Chen Ri-Xin , Wei Wen-Su , Li Yong-Hong , Feng Zi-Hao , Tan Lei , Chen Jie-Wei , Yuan Gang-Jun , Chen Si-Liang , Guo Sheng-Jie , Xiao Kang-Hua , Liu Zhuo-Wei , Luo Jun-Hang , Zhou Fang-Jian , Xie Dan
Published: April 2023

Supplementary Figure S1. CircPRMT5 is upregulated in UCB cells. Supplementary Figure S2. CircPRMT5 promotes migration and invasion of UCB cells. Supplementary Figure S3. CircPRMT5 contains multiple target sites of miRNAs. Supplementary Figure S4. CircPRMT5 promotes migration and invasion of UCB cells by reducing the inhibitory effect of miR-30c via sponge activity. Supplementary Figure S5. SNAIL1 is a target of miR-30c. Supplementary Figure S6. Representative images of SNAIL1 and E-cadherin expressions examined by IHC in UCB tissues with high (left) and low (right) expression of circPRMT5. Supplementary Figure S7. The correlation between expressions of SNAIL1 and miR-200 family in UCB tissues derived from TCGA database. Supplementary Figure S8. CircPRMT5 was secreted into exosomes derived from serum and urine of UCB patients. Supplementary Table S1. Correlation between expression of circPRMT5 and patients' clinicopathological variables in UCB patients Supplementary Table S2. The up-regulated and down-regulated circRNAs in UBCs Supplementary Table S3. Correlation of miR-30c expression with patients' clinicopathological variables in TCGA UCB cohorts Supplementary Table S4. Correlation of circPRMT5 expression in serum exosomes with patients' clinicopathological variables in 71 cases of UCB
Figure S1 from Detection of Gastric Cancer with Novel Methylated DNA Markers: Discovery, Tissue Validation, and Pilot Testing in Plasma
Authors: Anderson Bradley W. , Suh Yun-Suhk , Choi Boram , Lee Hyuk-Joon , Yab Tracy C. , Taylor William R. , Dukek Brian A. , Berger Calise K. , Cao Xiaoming , Foote Patrick H. , Devens Mary E. , Boardman Lisa A. , Kisiel John B. , Mahoney Douglas W. , Slettedahl Seth W. , Allawi Hatim T. , Lidgard Graham P. , Smyrk Thomas C. , Yang Han-Kwang , Ahlquist David A.
Published: April 2023

Supplemental Figure 1: Quantitative allele-specific real-time target and signal amplification (QuARTS) assay.
Supplementary table 1 from Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy
Authors: Panditharatna Eshini , Kilburn Lindsay B. , Aboian Mariam S. , Kambhampati Madhuri , Gordish-Dressman Heather , Magge Suresh N. , Gupta Nalin , Myseros John S. , Hwang Eugene I. , Kline Cassie , Crawford John R. , Warren Katherine E. , Cha Soonmee , Liang Winnie S. , Berens Michael E. , Packer Roger J. , Resnick Adam C. , Prados Michael , Mueller Sabine , Nazarian Javad
Published: April 2023

Assessing specificity of ddPCR platform by testing non-CNS malignant pediatric CSF and plasma.
Figure S2 from False-Positive Plasma Genotyping Due to Clonal Hematopoiesis
Authors: Hu Yuebi , Ulrich Bryan C. , Supplee Julianna , Kuang Yanan , Lizotte Patrick H. , Feeney Nora B. , Guibert Nicolas M. , Awad Mark M. , Wong Kwok-Kin , Jänne Pasi A. , Paweletz Cloud P. , Oxnard Geoffrey R.
Published: April 2023

Droplet digital PCR (ddPCR) of the peripheral blood cell DNA from 4 cases with JAK2 V617F found on plasma next-generation sequencing (NGS). In each, the JAK2 mutation was detected (top), consistent with clonal hematopoiesis, while not detected in a control sample.
Supplementary Table 2. from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients
Authors: Gordevičius Juozas , Kriščiūnas Algimantas , Groot Daniel E. , Yip Steven M. , Susic Miki , Kwan Andrew , Kustra Rafal , Joshua Anthony M. , Chi Kim N. , Petronis Art , Oh Gabriel
Published: April 2023

Clinical information of all samples.
Supplemental Figure S1 from Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival
Authors: Subbiah Vivek , Lamhamedi-Cherradi Salah-Eddine , Cuglievan Branko , Menegaz Brian A. , Camacho Pamela , Huh Winston , Ramamoorthy Vandhana , Anderson Pete M. , Pollock Raphael E. , Lev Dina C. , Qiao Wei , McAleer Mary Frances , Benjamin Robert S. , Patel Shreyaskumar , Herzog Cynthia E. , Daw Najat C. , Feig Barry W. , Lazar Alexander J. , Hayes-Jordan Andrea , Ludwig Joseph A.
Published: April 2023

Response for front-line chemotherapy
Figure S5 from A T-cell–engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer
Authors: Iizuka Akira , Nonomura Chizu , Ashizawa Tadashi , Kondou Ryota , Ohshima Keiichi , Sugino Takashi , Mitsuya Koichi , Hayashi Nakamasa , Nakasu Yoko , Maruyama Kouji , Yamaguchi Ken , Akiyama Yasuto
Published: April 2023

Effect of anti-B7-H4 BsAb on the growth of B7-H4-positive breast cancer cell lines, HCC-1954 and HCC-1569
Figure S1 from A T-cell–engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer
Authors: Iizuka Akira , Nonomura Chizu , Ashizawa Tadashi , Kondou Ryota , Ohshima Keiichi , Sugino Takashi , Mitsuya Koichi , Hayashi Nakamasa , Nakasu Yoko , Maruyama Kouji , Yamaguchi Ken , Akiyama Yasuto
Published: April 2023

B7-H4 gene expression levels of various cancers in the HOPE project and the prognostic significance
Supplementary Table 11 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Authors: Hamy Anne-Sophie , Bonsang-Kitzis Hélène , De Croze Diane , Laas Enora , Darrigues Lauren , Topciu Lucian , Menet Emmanuelle , Vincent-Salomon Anne , Lerebours Florence , Pierga Jean-Yves , Brain Etienne , Feron Jean-Guillaume , Benchimol Gabriel , Lam Giang-Thanh , Laé Marick , Reyal Fabien
Published: April 2023

Supplementary Table 11
Supplementary Data from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Authors: Hamy Anne-Sophie , Bonsang-Kitzis Hélène , De Croze Diane , Laas Enora , Darrigues Lauren , Topciu Lucian , Menet Emmanuelle , Vincent-Salomon Anne , Lerebours Florence , Pierga Jean-Yves , Brain Etienne , Feron Jean-Guillaume , Benchimol Gabriel , Lam Giang-Thanh , Laé Marick , Reyal Fabien
Published: April 2023

supplementary figures
Supplementary Table 4 from Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade
Authors: Georgiadis Andrew , Durham Jennifer N. , Keefer Laurel A. , Bartlett Bjarne R. , Zielonka Magdalena , Murphy Derek , White James R. , Lu Steve , Verner Ellen L. , Ruan Finey , Riley David , Anders Robert A. , Gedvilaite Erika , Angiuoli Sam , Jones Siân , Velculescu Victor E. , Le Dung T. , Diaz Luis A. , Sausen Mark
Published: April 2023

58 Gene List for Plasma Analyses
Supplementary Legend from First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors
Authors: Tao Jessica J. , Cangemi Nicholas A. , Makker Vicky , Cadoo Karen A. , Liu Joyce F. , Rasco Drew W. , Navarro Willis H. , Haqq Christopher M. , Hyman David M.
Published: April 2023

Supplementary Legend
Supplementary Table 1 from Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non–Small-Cell Lung Cancer
Authors: Pailler Emma , Faugeroux Vincent , Oulhen Marianne , Mezquita Laura , Laporte Mélanie , Honoré Aurélie , Lecluse Yann , Queffelec Pauline , NgoCamus Maud , Nicotra Claudio , Remon Jordi , Lacroix Ludovic , Planchard David , Friboulet Luc , Besse Benjamin , Farace Françoise
Published: April 2023

Supplementary Table 1
Supplementary Table S1-S4. from Alterations in DNA Damage Repair Genes in Primary Liver Cancer
Authors: Lin Jianzhen , Shi Junping , Guo Honglin , Yang Xu , Jiang Yan , Long Junyu , Bai Yi , Wang Dongxu , Yang Xiaobo , Wan Xueshuai , Zhang Lei , Pan Jie , Hu Ke , Guan Mei , Huo Li , Sang Xinting , Wang Kai , Zhao Haitao
Published: April 2023

Supplementary Table S1-S4.
Supplementary Data from Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations
Authors: Suehara Yoshiyuki , Alex Deepu , Bowman Anita , Middha Sumit , Zehir Ahmet , Chakravarty Debyani , Wang Lu , Jour George , Nafa Khedoudja , Hayashi Takuo , Jungbluth Achim A. , Frosina Denise , Slotkin Emily , Shukla Neerav , Meyers Paul , Healey John H. , Hameed Meera , Ladanyi Marc
Published: April 2023

Supplementary Figure 1 legend
Supplementary Data from Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial
Authors: Landi Lorenza , Chiari Rita , Tiseo Marcello , D'Incà Federica , Dazzi Claudio , Chella Antonio , Delmonte Angelo , Bonanno Laura , Giannarelli Diana , Cortinovis Diego Luigi , de Marinis Filippo , Borra Gloria , Morabito Alessandro , Gridelli Cesare , Galetta Domenico , Barbieri Fausto , Grossi Francesco , Capelletto Enrica , Minuti Gabriele , Mazzoni Francesca , Verusio Claudio , Bria Emilio , Alì Greta , Bruno Rossella , Proietti Agnese , Fontanini Gabriella , Crinò Lucio , Cappuzzo Federico
Published: April 2023

Supplementary information of the manuscript Table S1. Outcome to prior therapy in cohort A and cohort B Table S2. Response according to molecular profile in Cohort A Table S3. Response according to molecular profile in Cohort B Tables S4. Efficacy outcome according to type of MET deregulation Table S5. Adverse events (AEs) in Cohort A and Cohort B Table S6. List of serious adverse events (SAE) as reported by investigators Table S7. List of all participating Institutions
Supplementary Figure 1 from Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA
Authors: Kaseb Ahmed O. , Sánchez Nora S. , Sen Shiraj , Kelley Robin K. , Tan Benjamin , Bocobo Andrea G. , Lim Kian H. , Abdel-Wahab Reham , Uemura Marc , Pestana Roberto Carmagnani , Qiao Wei , Xiao Lianchun , Morris Jeffrey , Amin Hesham M. , Hassan Manal M. , Rashid Asif , Banks Kimberly C. , Lanman Richard B. , Talasaz AmirAli , Mills-Shaw Kenna R. , George Bhawana , Haque Abedul , Raghav Kanwal P.S. , Wolff Robert A. , Yao James C. , Meric-Bernstam Funda , Ikeda Sadakatsu , Kurzrock Razelle
Published: April 2023

Supplementary Figure 1
Figure S3 from TFEB Mediates Immune Evasion and Resistance to mTOR Inhibition of Renal Cell Carcinoma via Induction of PD-L1
Authors: Zhang Cai , Duan Yaqi , Xia Minghui , Dong Yuting , Chen Yufei , Zheng Lu , Chai Shuaishuai , Zhang Qian , Wei Zhengping , Liu Na , Wang Jing , Sun Chaoyang , Tang Zhaohui , Cheng Xiang , Wu Jie , Wang Guoping , Zheng Fang , Laurence Arian , Li Bing , Yang Xiang-Ping
Published: April 2023

TFEB expression within RCC tissues and correlation of TFEB and PD-L1 expression in RCCs
Figure S2 from TFEB Mediates Immune Evasion and Resistance to mTOR Inhibition of Renal Cell Carcinoma via Induction of PD-L1
Authors: Zhang Cai , Duan Yaqi , Xia Minghui , Dong Yuting , Chen Yufei , Zheng Lu , Chai Shuaishuai , Zhang Qian , Wei Zhengping , Liu Na , Wang Jing , Sun Chaoyang , Tang Zhaohui , Cheng Xiang , Wu Jie , Wang Guoping , Zheng Fang , Laurence Arian , Li Bing , Yang Xiang-Ping
Published: April 2023

No effect of TFEB on RCC tumor growth in nude mice
Figure S3 from Evolutionary Routes in Metastatic Uveal Melanomas Depend on MBD4 Alterations
Authors: Rodrigues Manuel , Mobuchon Lenha , Houy Alexandre , Alsafadi Samar , Baulande Sylvain , Mariani Odette , Marande Benjamin , Ait Rais Khadija , Van der Kooij Monique K. , Kapiteijn Ellen , Gassama Sieta , Gardrat Sophie , Barnhill Raymond L. , Servois Vincent , Dendale Rémi , Putterman Marc , Tick Sarah , Piperno-Neumann Sophie , Cassoux Nathalie , Pierron Gaëlle , Waterfall Joshua J. , Roman-Roman Sergio , Mariani Pascale , Stern Marc-Henri
Published: April 2023

Supplementary figure 3 - Summary diagrams illustrating the median SNV heterogeneity ratios.
Supplementary Tables S5-8 from Genome-wide RNAi Screening Identifies RFC4 as a Factor That Mediates Radioresistance in Colorectal Cancer by Facilitating Nonhomologous End Joining Repair
Authors: Wang Xue-Cen , Yue Xin , Zhang Rong-Xin , Liu Ting-Yu , Pan Zhi-Zhong , Yang Meng-Jie , Lu Zhen-Hai , Wang Zi-Yang , Peng Jian-Hong , Le Li-Yuan , Wang Gao-Yuan , Peng Qi-Hua , Meng Yuan , Huang Wenlin , Liu Ran-Yi
Published: April 2023

Supplementary Tables S5 & S6 show the candidate genes picked out in HCT116 and HT29 cells; Supplementary Tables S7 & S8 show the proteins might bind with RFC4, detected by IP-MS in HCT116 and HT29 cells.
Supplementary Table S4 from Genome-wide RNAi Screening Identifies RFC4 as a Factor That Mediates Radioresistance in Colorectal Cancer by Facilitating Nonhomologous End Joining Repair
Authors: Wang Xue-Cen , Yue Xin , Zhang Rong-Xin , Liu Ting-Yu , Pan Zhi-Zhong , Yang Meng-Jie , Lu Zhen-Hai , Wang Zi-Yang , Peng Jian-Hong , Le Li-Yuan , Wang Gao-Yuan , Peng Qi-Hua , Meng Yuan , Huang Wenlin , Liu Ran-Yi
Published: April 2023

Supplementary Table S4 shows the correlation of clinicopathological parameters and RFC4 expression.
Supplementary Data from Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer
Authors: Leighl Natasha B. , Page Ray D. , Raymond Victoria M. , Daniel Davey B. , Divers Stephen G. , Reckamp Karen L. , Villalona-Calero Miguel A. , Dix Daniel , Odegaard Justin I. , Lanman Richard B. , Papadimitrakopoulou Vassiliki A.
Published: April 2023

Supplementary Table 1: Detailed assessment of each of the 282 patients. For each of the 282 patients, genomic testing outcome for each modality and each of the eight genomic biomarkers is outlined, as well as KRAS and tissue assessed PD-L1 expression. "-" denotes where mutations in these genes were not assessed. Supplementary Table 2: Comparison of tissue versus cfDNA results for biomarkers in newly diagnosed metastatic NSCLC. For EGFR, four patients had baseline EGFR tissue results that were "negative". Upon review, patients received targeted EGFR testing that did not assess for the mutation identified in cfDNA. Therefore, they were coded as "not assessed" in these expanded tables but were "negative" for the primary endpoint. Supplementary Table 3: Detailed results for patients with positive results. For all 221 patients with a guideline-recommended biomarker detected in cfDNA or tissue, KRAS detected in cfDNA or tissue, or PDL-1 over-expression on tissue Supplementary Table 4: Co-occurring guideline-recommended biomarker and PD-L1 overexpression. Supplementary Table 5: Tissue versus cfDNA analysis Supplementary Table 6: Sites and Principal Investigators for the NILE (Non-invasive versus Invasive Lung Evaluation)
Supplementary Table 3 from Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas
Authors: Capdevila Jaume , Arqués Oriol , Hernández Mora Jose Ramón , Matito Judit , Caratù Ginevra , Mancuso Francesco M. , Landolfi Stefania , Barriuso Jorge , Jimenez-Fonseca Paula , Lopez Lopez Carlos , Garcia-Carbonero Rocio , Hernando Jorge , Matos Ignacio , Paolo Nuciforo , Hernández-Losa Javier , Esteller Manel , Martínez-Cardús Anna , Tabernero Josep , Vivancos Ana , Palmer Héctor G.
Published: April 2023

Supplementary Table 3
Supplementary Table S3 from Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer
Authors: Meric-Bernstam Funda , Johnson Amber M. , Dumbrava Ecaterina E. Ileana , Raghav Kanwal , Balaji Kavitha , Bhatt Michelle , Murthy Rashmi K. , Rodon Jordi , Piha-Paul Sarina A.
Published: April 2023

HER2 targeted therapy combinations
Supplementary Data from Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy
Authors: Foidart Pierre , Yip Cassandre , Radermacher Jean , Blacher Silvia , Lienard Mehdi , Montero-Ruiz Laetitia , Maquoi Erik , Montaudon Elodie , Château-Joubert Sophie , Collignon Joëlle , Coibion Michel , Jossa Véronique , Marangoni Elisabetta , Noël Agnès , Sounni Nor Eddine , Jerusalem Guy
Published: April 2023

Supplemental data include a Supplemental Table-1, Supplemental Figure 1, Supplemental Figure 2, Supplemental Figure 3, Supplemental Figure 4, Supplemental Figure 5 and Supplemental Figure 6. Supplemental Table-1 is related to Figure 1 Supplemental Figure 1 is related to Figure 2 Supplemental Figure 2 is related to Figure 5 Supplemental Figures 3-5 are related to Figure 6 Supplemental Figure 6 is related to Figure 1 and Figure 5
Figure S3 from LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth
Authors: Erice Oihane , Narayanan Shruthi , Feliu Iker , Entrialgo-Cadierno Rodrigo , Malinova Antonia , Vicentini Caterina , Guruceaga Elizabeth , Delfino Pietro , Trajkovic-Arsic Marija , Moreno Haritz , Valencia Karmele , Blanco Ester , Macaya Irati , Öhlund Daniel , Khatri Purvesh , Lecanda Fernando , Scarpa Aldo , Siveke Jens T. , Corbo Vincenzo , Ponz-Sarvise Mariano , Vicent Silve
Published: April 2023

Suppl. Figure 3. A. Immunoblot of LAMC2 upon Lamc2 knockdown by a specific shRNA in 511950 and PM12167 PDAC mouse cell lines. B. Quantification of organoid number upon LAMC2 knockdown by a specific shRNA in 511950 and PM12167 PDAC mouse cell lines.C. Quantification of organoid area (AU) in same cell lines as in B. Error bars correspond to s.d. D. Immunoblot of LAMC2 upon LAMC2 knockdown in HPAFII cell line. E. Quantification of organoid number and organoid area (AU) in HPAFII cell line expressing a TET-inducible shRNA against LAMC2 (bottom) or a control shRNA (top) cultured in 3D. F. Representative images of the subcutaneous tumors from PATU8902 cells expressing a TET-inducible shRNA against LAMC2 or a control shRNA at sacrifice. G. Representative images of the subcutaneous tumors from HPAFII cells expressing a TET-inducible shRNA against LAMC2 or a control shRNA at sacrifice. H and I. Representative IHC of LAMC2 expression in subcutaneous tumors from PATU8902 (H) and HPAFII (I) cells expressing a TET-inducible shRNA against LAMC2 or a control shRNA at sacrifice J. Representative images of the tumors derived from intrapancreatic injection of PATU8902 cells expressing a TET-inducible shRNA against LAMC2 or a control shRNA at sacrifice. K. Representative images of the subcutaneous tumors from PM12167 mouse cells expressing a shRNA against Lamc2 or a control shRNA at sacrifice. L and M. Representative images of the subcutaneous (sc) tumors from PATU8902 and HPAFII expressing a TET-inducible shRNA against LAMC2 or a control shRNA at sacrifice. ShRNA expression induced after tumor establishment at Day 8. N and O. Representative IHC of LAMC2 expression in subcutaneous tumors (Tx) from PATU8902 (H) and HPAFII (I) cells expressing a TET-inducible shRNA against LAMC2 or a control shRNA, shRNA expression was induced at day 8 of tumor establishment. P. Quantification of Ki67 IHC staining in PATU8902 and HFAFII xenograft models: SC and Tx. Q. Quantification of cleaved caspase3 IHC staining in PATU8902 and HFAFII xenograft models: SC and Tx.